Mavrilimumab
Mavrilimumab is an antibody pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against granulocyte-macrophage colony-stimulating factor receptor subunit alpha.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
12 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Covid-19 | D000086382 | — | U07.1 | — | 5 | 1 | — | — | 5 |
| Pneumonia | D011014 | EFO_0003106 | J18 | — | 5 | 1 | — | — | 5 |
| Inflammation | D007249 | MP_0001845 | — | — | 5 | 1 | — | — | 5 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Rheumatoid arthritis | D001172 | EFO_0000685 | M06.9 | 1 | 4 | — | — | — | 5 |
| Arthritis | D001168 | EFO_0005856 | M05-M14 | 1 | 4 | — | — | — | 5 |
| Respiratory insufficiency | D012131 | — | J96.9 | — | 4 | — | — | — | 4 |
| Severe acute respiratory syndrome-related coronavirus | D045473 | NCBITaxon_227859 | — | — | 2 | — | — | — | 2 |
| Sars-cov-2 | D000086402 | — | — | — | 2 | — | — | — | 2 |
| Necrosis | D009336 | — | — | — | 1 | — | — | — | 1 |
| Respiratory distress syndrome | D012128 | EFO_1000637 | J80 | — | 1 | — | — | — | 1 |
| Viral pneumonia | D011024 | EFO_0007541 | J12.9 | — | 1 | — | — | — | 1 |
| Giant cell arteritis | D013700 | EFO_1001209 | M31.6 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Mavrilimumab |
| INN | mavrilimumab |
| Description | Mavrilimumab (human mab) |
| Classification | Antibody |
| Drug class | monoclonal antibodies |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL1743039 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | 1158JD1P9A (ChemIDplus, GSRS) |
Target
Agency Approved
CSF2RA
CSF2RA
Organism
Homo sapiens
Gene name
CSF2RA
Gene synonyms
CSF2R, CSF2RY
NCBI Gene ID
Protein name
granulocyte-macrophage colony-stimulating factor receptor subunit alpha
Protein synonyms
alpha-GM-CSF receptor, CD116, CD116 antigen, CDw116, colony stimulating factor 2 receptor alpha subunit, colony stimulating factor 2 receptor, alpha, low-affinity (granulocyte-macrophage), GM-CSF receptor alpha subunit, granulocyte-macrophage colony-stimulating factor receptor alpha chain
Uniprot ID
Mouse ortholog
—
—
Alternate
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 593 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use